Board of Directors
Rich Whitely, MD
Virologist
-
Gilead's Board of Director
-
Distinguished Professor Loeb Scholar Chair in Pediatrics, and Professor of Microbiology, Medicine and Neurosurgery, UAB
-
Co-Founder & Co-Director,
-
Alabama Drug Discovery Alliance
-
380 Publications
-
Obama H1N1 Task Force
-
Remdesivir was Originally Developed by Dr Whitley’s team at UAB
Abel DeLaRosa, PhD
Virologist
-
CEO, Director, co-founder of Antios Therapeutics
-
Chief Scientific Officer of Drug Innovation Ventures at Emory
-
Led acquisition of Pharmasset by Gilead Sciences (NASDAQ: GILD) for $11.5 billion in 2012
-
Led Drug Development Programs for the Treatment of HIV, Hepatitis B and C, including Sofosbuvir
John Thomas, CPA
CFO/Director/Audit Chair
-
CorMatrix Cardiovascular DemeRx, Inc.
-
MiMedx Group, Inc.
-
DARA BioSciences
-
GMP Companies
-
MRI Interventions
-
EnterMed, Inc.
-
Medicis Pharm Corp.
-
CytRx Corp
Rick Keefer
Director
-
30-year Pharma industry veteran with broad-based experience in leading commercial operations.
-
Seven-time winner of Pharma Voice’s top 100 leaders in healthcare
-
Executive roles at Pharmacia, Pfizer, Wyeth, Biovail and Publicis Health
Skip Pridgen, MD Founder
Director
-
Company Founder
-
Board- certified surgeon practicing with Tuscaloosa Surgical Associates, P.C.
-
Spent nearly 20 years searching for effective treatments in IBS, FM, and CFS/ME
-
Served as a physician and surgeon in the United States Navy
Greg Duncan
Director
-
FPO
Rick Burch
Director
-
FPO